Did PolyNovo's Fall Catch You Out? Here's What The Bears Saw

If you had skimmed past PolyNovo at the start of 2026, thinking the debate between bullish expansion hopes and cost concerns looked too finely balanced to touch, the outcome would have looked very different to those who stayed in. Holding PolyNovo from the start of the year would have meant a 29.2% loss, including dividends. With that result now on the table, which assumptions in the 2025 research would you want to recheck first?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

The move put PolyNovo in the middle of this trade. Scan 6 healthcare AI stocks for other companies exposed to it.

The Two Stories PolyNovo Investors Were Weighing

The shares cost A$1.23 at the start of the period, and PolyNovo sat between two sharply different stories about where the business might head next.

The bullish narrative saw fair value at A$1.81, based on assumptions that revenue could compound at 21.4% with profit margins reaching 17.8%, helped by expanding manufacturing capacity and broader use of NovoSorb products.

The bearish case put fair value at A$1.15 and focused on rising global healthcare cost pressures and tighter reimbursement pushing hospitals toward cheaper options, which could squeeze margins even if sales kept growing.

What The Results Changed For The PolyNovo Story

The clearest new clue came from H2 2026, when PolyNovo’s revenue moved from A$69.164m in H2 2025 to A$79.522m. This supported the bullish focus on capacity expansion and wider product use. Profit told a different story, with net income slipping from A$9.876m to A$7.338m and margin falling from 14.3% to 9.2%. The period therefore cut both ways.

The hinge assumption here was margin expansion alongside higher sales. When you review another medtech stock, line up revenue, net income and net margin across periods to see whether higher volumes are actually turning into better profitability.

What PolyNovo's Lower Price Is Asking You To Believe

PolyNovo now trades at A$0.89, leaving investors who held from the start of the year with a 29.2% loss. The analyst consensus Narrative on Simply Wall St still places its Fair Value above that level, based on how current cash flow and margins are being read.

The Narrative leans on broader NovoSorb wound use and Rest of World momentum rather than entirely new territories. For that higher figure to be reached, a buyer today would need to believe NovoSorb adoption in complex wounds and outpatient settings can keep deepening without eroding profitability.

"The current narrative that PolyNovo is undervalued implies the share price does not fully reflect A$13.4 million of underlying EBITDA, A$9.4 million of free cash flow and very high gross margins that are already in place."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Looking Beyond PolyNovo’s Wounds

PolyNovo draws attention to treating difficult injuries and controlling procedure costs. Close behind, another problem keeps healthcare executives awake at night.

As complex patients live longer and require ongoing support, bills and benefit decisions quietly pile up. Managing that administrative flow efficiently becomes its own bottleneck.

One large health services group concentrates on that pinch point. Its software, analytics and automation support benefit plans, pharmacy programs and clinical decisions.

The goal is straightforward. Reduce waste in claims, call centers and documentation so more spending reaches actual treatment. If that push succeeds, this business could occupy a very different place in healthcare budgets.

That argument has a Narrative and a number behind it. → See the company one Narrative values 19% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com